Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like peptide-1 (GLP-1) and...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2007
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994027/ |